Login

Journal Front Page

News & Events

  • Call for article for July 2025 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 June, 2025 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • April 2025 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 14, Issue 2 (April 2025 Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

SYNTHESIS, CHARACTERIZATION & BIOLOGICAL EVALUATION OF NOVEL 1H-SUBSTITUTED 2,4,5-TRIPHENYL IMIDAZOLE DERIVATIVES AS ANTICONVULSANT ACTIVITY

Nazneen Khatoon 1*, Govind Nayak 1, Neelima Mishra1, Parul Mehta1, Amidbodh Upadhyay 2, Mohd Lateef 3

1Lakshmi Narain College of Pharmacy, Bhopal (M.P)*
2Lakshmi Narain College of Technology and Science, Bhopal (M.P)
3JS. Singh Institute of Pharmacy, Sitapur (261207)

ABSTRACT

Epilepsy is a neuro pharmacological disorder that significantly impacts mental and physical well-being, with GABA inhibitors being a long-standing treatment option for convulsions. However, early attempts to utilize these inhibitors were limited by side effects associated with their irreversible mechanisms. Over time, researchers have shifted focus towards developing reversible and selective GABA-A inhibitors. In this study, we synthesized and evaluated novel triphenyl-1H-imidazole derivatives (N1to N6) for their anticonvulsant properties. The compounds were synthesized through a two-step procedure involving refluxing and characterized using various analytical techniques such as FT-IR, MS, and NMR. The anticonvulsant activity of the synthesized derivatives was assessed using the maximal electroshock seizure (MES) model in Swiss albino mice. Among the compounds tested, N2, N3, and N5 demonstrated significant anticonvulsant effects comparable to the standard drug, Phenytoin sodium. These findings suggest that these derivatives could serve as potential candidates for the treatment of epilepsy and other neuro pharmacological disorders. Further research on structural modifications, selectivity, and reversibility is needed to optimize their efficacy and minimize side effects. Additionally, these compounds may be explored for other biological activities such as antioxidant, anti-inflammatory, and antidepressant properties, which could open new therapeutic avenues for the treatment of neurodegenerative disorders.

Keywords: Epilepsy, Anticonvulsant, Triphenyl-1H-imidazole, GABA inhibitors, Maximal Electroshock Seizure (MES).


[Full Text Article]